摘要
目的探讨阿立哌唑口崩片与舒必利治疗以阴性症状为主的育龄期女性精神分裂症患者的临床疗效和安全性。方法将120例以阴性症状为主的育龄期女性精神分裂症患者随机分为研究组和对照组，每组60例，分别口服阿立哌唑口崩片、舒必利治疗，观察8周。采用阴性症状量表、临床总体印象量表评定临床疗效，副反应量表评定不良反应。结果研究组显效率为70．7％、总有效率为91．4％，对照组分别为66．7％、89．5％，两组比较差异无显著性（Х^2=0．22、0．12，P〉0．05）。研究组未出现月经失调、泌乳及体质量增加等不良反应，不良反应发生率显著低于对照组（P〈0．01）。结论阿立哌唑口崩片治疗以阴性症状为主的育龄期女性精神分裂症患者疗效显著且与舒必利相当，但阿立哌唑口崩片治疗安全性更高，依从性更好。
Objective To explore the efficacy and safety of aripiprazole orally disintegrating tablet （AODT） vs. sulpiride in the treatment of childbearing-age female schizophrenia characterized by negative symptoms. Methods A total of 120 childbearing age female schizophrenics characterized by negative symptoms were randomly divided into research and control group of 60 ones each, they respectively took orally AODT and sulpiride for 8 weeks. Efficacies were assessed with the Scale for the Assessment of Negative Symptoms （SANS） and Clinical Global Impression （CGI） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results The obvious and total effective rate were respectively 70.7% and 91.4% in research and 66.7% and 89.5% in control group, which showed no significant group differ- ences （Х^2=0.22,0. 12,P〈0.05）. Research group had no such adverse reactions as menstrual disorder, lactation, weight gain and so on, incidences of adverse reactions were significantly lower in research than control group （P〈0.01）. Conclusion AODT has an evident effect equivalent to sulpiride in the treatment of childbearing age female schizophrenia characterized by negative symptoms, but the former has higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2013年第5期402-404,共3页
Journal of Clinical Psychosomatic Diseases
